GCG and metabolic dysfunction-associated steatohepatitis: In this regard, different glucagon-like peptide-1 receptor agonists (GLP1-RAs) mimicking the action of GLP-1 have been developed and approved for the FDA to treat patients with T2DM, and their therapeutic effects have also been slightly explored in patients with NASH [193,226].